Spondyloarthritis & psoriatic arthritis
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors
Authors' conclusion
A BNT162b2 booster dose should be recommended in PsA patients on TNFi as its administration restores anti-SARS-CoV-2 IgG levels similar to healthy individuals.
Study context
- Population
- Patients with PsA on TNF inhibitors (TNFi) receiving a BNT162b2 mRNA booster dose
- Participants
- 40 PsA patients
- Exposure
- PsA patients on TNFi vs matched healthy controls
- PsAn = 40
- Outcome
- Anti-SARS-CoV-2 IgG level decay after two-dose BNT162b2 vaccination and immunogenicity of the booster dose
Methodological details1:1 propensity score-matched healthy controls
- 1:1 propensity score-matched healthy controls
Main finding
As reported in the abstract
Anti-SARS-CoV-2 IgG level after booster dose · 15 days after third shot
P = 0.20
Observational data: associations, not effects.
Further findings
Mean
| Outcome | Before vaccination | After vaccination | P value |
|---|---|---|---|
| CDAI in PsA, before vs after vaccination | 6.68 (SD 4.38) | 4.95 (SD 4.20) | P = 0.19 |
- Anti-SARS-CoV-2 IgG level after booster dose · 15 days after the third shot
- P = 0.20
Anti-SARS-CoV-2 IgG level after booster dose · 15 days after the third shot
- Booster dose restored IgG levels to a similar extent in both groups
Clinical Disease Activity Index (CDAI) in PsA, before vs after vaccination
- CDAI did not change before and after vaccination
Original publication
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors. Clin Exp Rheumatol. Published 24 February 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →